This site is intended for healthcare professionals
  • Home
  • /
  • Journals
  • /
  • Uncategorised Disease
  • /
  • Roflumilast--a phosphodiesterase-4 inhibitor licen...

Roflumilast--a phosphodiesterase-4 inhibitor licensed for add-on therapy in severe COPD.

Read time: 1 mins
Published:25th Mar 2020
Author: Taegtmeyer AB, Leuppi JD, Kullak-Ublick GA.
Ref.:Swiss Med Wkly. 2012 Jul 25;142:w13628.
Register for free access to this exclusive healthcare learning resource

Why sign up with Medthority?

Develop your knowledge with our disease and condition focused Learning Zones

Access content from credible sources, including expert-led commentary, videos, podcasts, and webinars as well as clinical trials, treatment information and guidelines 

Personalised dashboard providing updates and recommendations for content within your areas of interest